{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:09:59Z","timestamp":1791839399856,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21091"],"award-info":[{"award-number":["21091"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2023"],"award-info":[{"award-number":["IG 2023"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 2021 - ID 26439"],"award-info":[{"award-number":["MFAG 2021 - ID 26439"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["28922"],"award-info":[{"award-number":["28922"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xcrm.2025.102313","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T14:45:52Z","timestamp":1756133152000},"page":"102313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models"],"prefix":"10.1016","volume":"6","author":[{"given":"Ksenija","family":"Slavic Obradovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem V.","family":"Artemov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Miotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula-Elena","family":"Traexler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha","family":"Pham Thi Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wernitznig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Antonietta","family":"Impagnatiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reniqua","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Popow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Carotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Tontsch-Grunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2708-1689","authenticated-orcid":false,"given":"Martin","family":"Aichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102313_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102313_bib2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: Biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2025.102313_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102323","article-title":"Bromodomain inhibitors and therapeutic applications","volume":"75","author":"Gajjela","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.xcrm.2025.102313_bib5","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/molecules28073043","article-title":"BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications","volume":"28","author":"To","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2025.102313_bib6","doi-asserted-by":"crossref","first-page":"11574","DOI":"10.1200\/JCO.2016.34.15_suppl.11574","article-title":"Effects of the novel BET inhibitor BI 894999 on upregulation of HEXIM1 in cancer cells and on antitumor activity in xenograft tumor models","volume":"34","author":"Tontsch-Grunt","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102313_bib7","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/s41388-018-0150-2","article-title":"The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML","volume":"37","author":"Gerlach","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102313_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41416-022-01815-5","article-title":"Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic","volume":"127","author":"Tontsch-Grunt","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102313_bib9","article-title":"Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials","volume":"11","author":"Sun","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102313_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours \u2014 past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102313_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011","article-title":"Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors","volume":"23","author":"Ramadoss","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2025.102313_bib12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/cells9020406","article-title":"Future Therapeutic Directions for Smac-Mimetics","volume":"9","author":"Morrish","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2025.102313_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2025.102313_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/B978-0-12-801430-1.00002-0","article-title":"Chapter Two IAP Family of Cell Death and Signaling Regulators","volume":"545","author":"Silke","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.xcrm.2025.102313_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcdb.2014.12.005","article-title":"Smac mimetics as IAP antagonists","volume":"39","author":"Fulda","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.xcrm.2025.102313_bib16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cell.2007.10.030","article-title":"IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-\u03baB Activation, and TNF\u03b1-Dependent Apoptosis","volume":"131","author":"Varfolomeev","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","article-title":"IAP Antagonists Target cIAP1 to Induce TNF\u03b1-Dependent Apoptosis","volume":"131","author":"Vince","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nature09852","article-title":"Catalytic activity of the caspase-8\u2013FLIPL complex inhibits RIPK3-dependent necrosis","volume":"471","author":"Oberst","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102313_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","article-title":"Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase","volume":"148","author":"Sun","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","article-title":"Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation","volume":"137","author":"Cho","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"Brd4 Coactivates Transcriptional Activation of NF-\u03baB via Specific Binding to Acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2025.102313_bib23","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/onc.2013.179","article-title":"Brd4 maintains constitutively active NF-\u03baB in cancer cells by binding to acetylated RelA","volume":"33","author":"Zou","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102313_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1158\/2326-6066.CIR-21-0224","article-title":"BET Inhibition Enhances TNF-Mediated Antitumor Immunity","volume":"10","author":"Wellinger","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2025.102313_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET Family Protein BRD4: An Emerging Actor in NF\u03baB Signaling in Inflammation and Cancer","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2025.102313_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.271","article-title":"Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents","volume":"7","author":"Klingbeil","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2025.102313_bib27","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1158\/0008-5472.CAN-09-1794","article-title":"Down-regulation of c-FLIP Enhances Death of Cancer Cells by Smac Mimetic Compound","volume":"69","author":"Cheung","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102313_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072967","article-title":"BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models","volume":"8","author":"Wyce","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2025.102313_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcp.2012.04.023","article-title":"Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells","volume":"84","author":"Chen","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102313_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2019.08.013","article-title":"BET protein targeting suppresses the PD-1\/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response","volume":"465","author":"Andrieu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2025.102313_bib31","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.7150\/jca.69375","article-title":"BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC","volume":"13","author":"Wang","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102313_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106381","article-title":"Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics","volume":"26","author":"Pinto","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.xcrm.2025.102313_bib33","doi-asserted-by":"crossref","first-page":"61469","DOI":"10.18632\/oncotarget.11129","article-title":"Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer","volume":"7","author":"Yamamoto","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102313_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/procel\/pwad033","article-title":"An orally available monovalent SMAC mimetic compound as a broad-spectrum antiviral","volume":"15","author":"Mei","year":"2024","journal-title":"Protein Cell"},{"key":"10.1016\/j.xcrm.2025.102313_bib35","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","article-title":"BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression","volume":"16","author":"Zhu","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102313_bib36","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/imt-2017-0185","article-title":"Regulation of innate and adaptive antitumor immunity by IAP antagonists","volume":"10","author":"Dougan","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.xcrm.2025.102313_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102313_bib38","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fonc.2019.00716","article-title":"CD49b, CD87, and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent Normal Fibroblasts in Murine Tumor Models","volume":"9","author":"Agorku","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102313_bib39","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.3389\/fimmu.2018.03115","article-title":"CCR7 Is Recruited to the Immunological Synapse, Acts as Co-stimulatory Molecule and Drives LFA-1 Clustering for Efficient T Cell Adhesion Through ZAP70","volume":"9","author":"Laufer","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102313_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2025.102313_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: A promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102313_bib42","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102313_bib43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2025.102313_bib44","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102313_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102313_bib46","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-16-2913","article-title":"Targeting Autocrine CCL5\u2013CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity","volume":"77","author":"Ban","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102313_bib47","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102313_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157281","article-title":"Combined noncanonical NF-\u03baB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo","volume":"132","author":"Falcinelli","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102313_bib49","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-19-2409","article-title":"A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin","volume":"26","author":"Arena","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102313_bib50","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41698-024-00706-7","article-title":"Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition","volume":"8","author":"Corti","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2025.102313_bib51","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1158\/1078-0432.CCR-22-0875","article-title":"Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer","volume":"28","author":"Durinikova","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102313_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nbt.2806","article-title":"Smac mimetics and innate immune stimuli synergize to promote tumor death","volume":"32","author":"Beug","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102313_bib53","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1038\/s41388-021-02041-8","article-title":"BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade","volume":"40","author":"Tong","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102313_bib54","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/s41418-020-0541-0","article-title":"Targeting triple-negative breast cancers with the Smac-mimetic birinapant","volume":"27","author":"Lalaoui","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2025.102313_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aar3451","article-title":"Tumor immune evasion arises through loss of TNF sensitivity","volume":"3","author":"Kearney","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xcrm.2025.102313_bib56","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS\u2013) vs. Alternatively Activated Macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102313_bib57","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/life11111240","article-title":"Prognostic Impact of Tumor-Associated Macrophages on Long-Term Oncologic Outcomes in Colorectal Cancer","volume":"11","author":"Shin","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.xcrm.2025.102313_bib58","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102313_bib59","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80721","article-title":"Arginase 1 is a key driver of immune suppression in pancreatic cancer","volume":"12","author":"Menjivar","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102313_bib60","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.1002\/cam4.6011","article-title":"The expanding role of IAP antagonists for the treatment of head and neck cancer","volume":"12","author":"Kansal","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2025.102313_bib61","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1016\/j.ymthe.2022.07.022","article-title":"BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma","volume":"30","author":"Zhang","year":"2022","journal-title":"Mol. Ther."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125003866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:22:58Z","timestamp":1772918578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125003866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666379125003866"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102313","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102313"}}